NEXTBio Capital Management LP Purchases New Position in Compass Therapeutics, Inc. $CMPX

NEXTBio Capital Management LP purchased a new stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,114,005 shares of the company’s stock, valued at approximately $5,982,000. Compass Therapeutics accounts for 3.5% of NEXTBio Capital Management LP’s investment portfolio, making the stock its 12th largest position.

A number of other large investors have also recently modified their holdings of CMPX. Strs Ohio purchased a new stake in shares of Compass Therapeutics in the first quarter valued at approximately $34,000. Creative Planning purchased a new stake in Compass Therapeutics during the second quarter worth $30,000. XTX Topco Ltd purchased a new stake in Compass Therapeutics during the second quarter worth $84,000. Invesco Ltd. lifted its holdings in Compass Therapeutics by 58.1% during the second quarter. Invesco Ltd. now owns 58,735 shares of the company’s stock worth $153,000 after buying an additional 21,578 shares during the period. Finally, Adage Capital Partners GP L.L.C. lifted its holdings in Compass Therapeutics by 11.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock worth $11,505,000 after buying an additional 449,868 shares during the period. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on CMPX. D. Boral Capital restated a “buy” rating and set a $30.00 target price on shares of Compass Therapeutics in a report on Monday, April 27th. Canaccord Genuity Group lowered their target price on Compass Therapeutics from $13.00 to $7.00 and set a “buy” rating for the company in a report on Tuesday, April 28th. Citigroup restated a “market outperform” rating on shares of Compass Therapeutics in a report on Thursday, June 4th. HC Wainwright restated a “buy” rating and set a $24.00 target price on shares of Compass Therapeutics in a report on Monday, April 27th. Finally, Wall Street Zen lowered Compass Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $12.91.

Compass Therapeutics Stock Performance

Shares of CMPX opened at $2.03 on Friday. The business’s 50-day moving average is $3.17 and its two-hundred day moving average is $4.76. The company has a market capitalization of $365.58 million, a P/E ratio of -4.95 and a beta of 0.89. Compass Therapeutics, Inc. has a fifty-two week low of $1.61 and a fifty-two week high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). Analysts forecast that Compass Therapeutics, Inc. will post -0.42 EPS for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.